| Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. | |
| | |
MedLine Citation:
|
PMID: 16585781 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The first four reviews in this series (Steinberg, D. 2004. J. Lipid Res. 45: 1583-1593; Steinberg, D. 2005. J. Lipid Res. 46: 179-190; Steinberg, D. 2005. J. Lipid Res. 46: 2037-2051; Steinberg, D. 2006. J. Lipid Res. 47: 1-14) traced the gradual accumulation of evidence, evidence of several different kinds, supporting the lipid hypothesis. They tracked the history from Anitschkow's 1913 classic work on the cholesterol-fed rabbit model to the breakthrough 1984 Coronary Primary Prevention Trial, the first large, randomized, double-blind primary intervention trial showing that decreasing blood cholesterol (using cholestyramine) significantly reduces coronary heart disease events. At that point, for the first time, decreasing blood cholesterol levels became an official national public health goal. Still, only a small fraction of patients at high risk were getting appropriate cholesterol-lowering treatment, and a number of important clinical questions remained unanswered. This final review in the series traces the early studies that led to the discovery of the statins and briefly reviews the now familiar large-scale clinical trials demonstrating their safety and their remarkable effectiveness in reducing coronary heart disease morbidity and mortality. |
| | |
Authors:
|
Daniel Steinberg |
Publication Detail:
|
Type: Comment; Historical Article; Journal Article; Review Date: 2006-04-03 |
Journal Detail:
|
Title: Journal of lipid research Volume: 47 ISSN: 0022-2275 ISO Abbreviation: J. Lipid Res. Publication Date: 2006 Jul |
Date Detail:
|
Created Date: 2006-06-29 Completed Date: 2006-09-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376606 Medline TA: J Lipid Res Country: United States |
Other Details:
|
Languages: eng Pagination: 1339-51 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of California-San Diego, La Jolla, CA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Animals Atherosclerosis / drug therapy*, etiology*, history, metabolism Carcinogens / toxicity Cholesterol / history, metabolism* Clinical Trials as Topic Coronary Disease / drug therapy, prevention & control Female History, 20th Century History, 21st Century Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / history, therapeutic use*, toxicity Male |
| Chemical | |
Reg. No./Substance:
|
0/Carcinogens; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 57-88-5/Cholesterol |
| Comments/Corrections | |
Comment On:
|
J Lipid Res. 2004 Sep;45(9):1583-93
[PMID:
15102877
]
J Lipid Res. 2005 Feb;46(2):179-90 [PMID: 15547293 ] J Lipid Res. 2006 Jan;47(1):1-14 [PMID: 16227628 ] J Lipid Res. 2005 Oct;46(10):2037-51 [PMID: 15995167 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Levels of glycine betaine in growing cells and spores of Bacillus species and lack of effect of glyc...
Next Document: Enzyme activity assay for cholesterol 27-hydroxylase in mitochondria.